Showing 1 - 6 results of 6 for search 'Anne Perdrix', query time: 0.03s Refine Results
  1. 1
    PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

    PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies by Anne Perdrix, Ahmad Najem, Sven Saussez, Ahmad Awada, Fabrice Journe, Ghanem Ghanem, Mohammad Krayem

    Published 2017-12-01
    Get full text
    Article
  2. 2
    Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy

    Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclo... by Matteo Lambertini, Matteo Lambertini, Nathalie Olympios, Justine Lequesne, Céline Calbrix, Maxime Fontanilles, Maxime Fontanilles, Agnès Loeb, Marianne Leheurteur, Isabelle Demeestere, Frédéric Di Fiore, Frédéric Di Fiore, Anne Perdrix, Anne Perdrix, Florian Clatot, Florian Clatot

    Published 2019-07-01
    Get full text
    Article
  3. 3
    Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

    Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients by Violette Allouchery, Ludivine Beaussire, Anne Perdrix, David Sefrioui, Laetitia Augusto, Cécile Guillemet, Nasrin Sarafan-Vasseur, Frédéric Di Fiore, Florian Clatot

    Published 2018-05-01
    Get full text
    Article
  4. 4
    Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma

    Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma by Aurélien Drouyer, Ludivine Beaussire, Pauline Jorda, Marianne Leheurteur, Cécile Guillemet, Anca Berghian, Dragos Georgescu, Frédéric Di Fiore, Anne Perdrix, Florian Clatot

    Published 2023-11-01
    Get full text
    Article
  5. 5
    Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients

    Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients by Violette Allouchery, Anne Perdrix, Céline Calbrix, Anca Berghian, Justine Lequesne, Maxime Fontanilles, Marianne Leheurteur, Pascaline Etancelin, Nasrin Sarafan-Vasseur, Frédéric Di Fiore, Florian Clatot

    Published 2021-12-01
    Get full text
    Article
  6. 6
    Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

    Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer by Florian Clatot, Anne Perdrix, Ludivine Beaussire, Justine Lequesne, Christelle Lévy, George Emile, Michael Bubenheim, Sigrid Lacaille, Céline Calbrix, Laetitia Augusto, Cécile Guillemet, Cristina Alexandru, Maxime Fontanilles, David Sefrioui, Lucie Burel, Sabine Guénot, Doriane Richard, Nasrin Sarafan-Vasseur, Frédéric Di Fiore

    Published 2020-05-01
    Get full text
    Article

Search Tools: